EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization-embryo transfer



Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization-embryo transfer



Fertility and Sterility 93(2): 554-569



To study the outcome of IVF-ET in women who used vaginal P (vaginal P(4)) versus those who used P in oil via IM injection (IM-P(4)) for luteal support. Retrospective cohort. Tertiary referral infertility center. A cohort of 544 women. In 145 women, vaginal P(4) was used, while in 399 women, IM-P(4) was used for luteal support. The primary outcome was ongoing pregnancy rate. Secondary outcomes included other IVF-ET outcomes: rates of clinical pregnancy and pregnancy loss (chemical and miscarriage) and serum P levels during the luteal phase and early pregnancy. Women who used vaginal P(4) for luteal support had ongoing pregnancy rates (odds ratio [OR], 1.0675; 95% confidence interval [CI], 0.7587-1.5020) and rates of total pregnancy loss (OR, 1.0775; 95% CI, 0.7383-1.5727) that were not statistically different from those who used IM-P(4). During the luteal phase, women who used vaginal P(4) had mean serum P levels that were not statistically different from those who used IM-P(4). However, during early pregnancy, mean P levels in pregnant women who used vaginal P(4) were statistically significantly higher. In women undergoing IVF-ET according to the GnRH agonist long protocol, luteal support with vaginal P(4) was associated with treatment outcomes that were no different from those associated with IM-P(4) luteal support.

(PDF emailed within 0-6 h: $19.90)

Accession: 056832013

Download citation: RISBibTeXText

PMID: 19362305

DOI: 10.1016/j.fertnstert.2009.02.047



Related references

Intramuscular progesterone (Gestone) versus vaginal progesterone suppository (Cyclogest) for luteal phase support in cycles of in vitro fertilization-embryo transfer: patient preference and drug efficacy. Fertility Research and Practice 3: 17-17, 2017

The vaginal micronized progesterone (Endometrin) is as effective as intramuscular progesterone for luteal support in women undergoing IVF-ET. Fertility and Sterility 90: S364-S365, 2008

Matched-samples comparison of intramuscular versus vaginal progesterone for luteal phase support after in vitro fertilization and embryo transfer. Fertility and Sterility 91(6): 2445-2450, 2008

Intramuscular versus vaginal administration of progesterone for luteal phase support after in vitro fertilization and embryo transfer. A comparative randomized study. Clinical and Experimental Obstetrics & Gynecology 26(3-4): 203-206, 2000

Luteal support after in-vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Human Reproduction 11(10): 2085-2089, 1996

Endocrinology: Luteal support after in-vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Human Reproduction 11(10): 2085-2089, 1996

Luteal support after in-vitro fertilization: Crinone 8 percent, a sustained release vaginal progesterone gel, versus utrogestan, an oral micronized progesterone. Human Reproduction (Oxford) 11(10): 2085-2089, 1996

Comparison of oral dydrogestrone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertility and Sterility 95(6): 1961-1965, 2011

Phase III trial of 8% vaginal progesterone gel for luteal phase support in Japanese women undergoing in vitro fertilization and fresh embryo transfer cycles. Reproductive Medicine and Biology 16(1): 52-57, 2017

Phase III trial of 8% vaginal progesterone gel for luteal phase support in Japanese women undergoing in vitro fertilization and fresh embryo transfer cycles. Reproductive Medicine and Biology 16(1): 52-57, 2017

A comparison of luteal phase support in graduated estradiol/progesterone replacement cycles using intramuscular progesterone alone versus combination with vaginal suppositories on outcome following frozen embryo transfer. Clinical and Experimental Obstetrics & Gynecology 32(2): 93-94, 2005

A prospective randomized multicentre study comparing vaginal progesterone gel and vaginal micronized progesterone tablets for luteal support after in vitro fertilization/intracytoplasmic sperm injection. Human Reproduction 27(12): 3467-3473, 2013

Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization-embryo transfer cycles: a prospective randomized study. Fertility and Sterility 94(7): 2596-2599, 2011

The vaginal progesterone, endometrin is associated with better outcome compared to intramuscular progesterone for luteal support in women with endometriosis undergoing IVF-ET. Fertility and Sterility 90: S363-S364, 2008

Intramuscular progesterone versus 8% Crinone vaginal gel for luteal phase support for day 3 cryopreserved embryo transfer. Fertility and Sterility 98(6): 1464-1469, 2013